Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Qin, Jian Zhong ^a,b   Upadhyay, Vivek ^a   Prabhakar, Bellur ^a   Maker, Ajay V ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b DALIAN UNIVERSITY   (China)

Author keywords

Colorectal liver metastases; Immunotherapy; LIGHT; Tumor infiltrating lymphocytes

Indexed keywords

CD69 ANTIGEN; GAMMA INTERFERON; HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 8; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR DISTRIBUTION; COLORECTAL CANCER; COLORECTAL CANCER LIVER METASTASIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNOASSAY; IMMUNOFLUORESCENCE MICROSCOPY; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LECTINS, C-TYPE; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PHENOTYPE; TH2 CELLS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 84875078093     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-70     Document Type: Article

References (35)

1. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573. 10.1002/cncr.24760, 3619726, 19998273.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
3. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Canc Epidemiol Biomarkers Prev 2009, 18:1688-1694.
4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics. CA Cancer J Clin 2011, 61:212-236. 2011, 10.3322/caac.20121, 21685461.
5. Penna C, Nordlinger B. Surgery of liver metastases from colorectal cancer: new promises. Br Med Bull 2002, 64:127-140. 10.1093/bmb/64.1.127, 12421730.
6. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992. 10.1093/annonc/mdn735, 19153115.
7. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2009, 29:1093-1102.
8. Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D'Angelica M, DeMatteo RP. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009, 16:2524-2530. 10.1245/s10434-009-0585-3, 19568816.
9. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y. Regulatory T Cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2012, 20:946-955.
10. Maker AV, Ito H, Mo Q, Qin L, DeMatteo RP, Blumgart LH, Fong Y, Maithel SK, Jarnagin WR, D'Angelica MI. Use of T-cell proliferation to predict survival and recurrence in patients with resected colorectal liver metastases. ASCO Meeting Abstr 2010, 28:10571.
11. Wang Y, Zhu M, Miller M, Fu YX. Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol Rev 2009, 229:232-243. 10.1111/j.1600-065X.2009.00762.x, 19426225.
12. Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX, Kast WM. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res 2010, 70:3955-3964. 10.1158/0008-5472.CAN-09-3773, 2873073, 20460520.
13. Yu P, Fu YX. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev 2008, 19:285-294. 10.1016/j.cytogfr.2008.04.004, 2517180, 18508404.
14. Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J. Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Canc 2010, 9:299.
15. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004, 5:141-149. 10.1038/ni1029, 14704792.
16. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 2009, 16:405-417. 410.1097/PAP.1090b1013e3181bb1096bdc, 10.1097/PAP.0b013e3181bb6bdc, 19851131.
17. Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick MB, Trougouboff P, Tomsho LD, Kim E, Low M. Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 2003, 27:563-570. 10.1097/00000478-200305000-00001, 12717242.
18. Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, Ben-Izhak O, Cohen HI, Trougouboff P, Bejhar J. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 2009, 33:126-133. 10.1097/PAS.0b013e31817ec2b1, 3500028, 18830122.
19. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
20. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58:3491-3494.
21. Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH, Schirrmacher V, Buchler MW. Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol 2008, 15:2310-2317. 10.1245/s10434-008-9971-5, 18521684.
22. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854. 10.1126/science.1076514, 1764179, 12242449.
23. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. 10.1056/NEJMoa1001294, 20818862.
24. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
25. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005, 12:1005-1016. 10.1245/ASO.2005.03.536, 1473970, 16283570.
26. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23:6043-6053. 10.1200/JCO.2005.06.205, 1473965, 16087944.
27. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005, 175:7746-7754. 1473972, 16301685.
28. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006, 29:455-463. 10.1097/01.cji.0000208259.73167.58, 2134804, 16799341.
29. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237-251.
30. Grimm M, Gasser M, Bueter M, Strehl J, Wang J, Nichiporuk E, Meyer D, Germer CT, Waaga-Gasser AM, Thalheimer A. Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. BMC Canc 2010, 10:82.
31. Endo T, Toda M, Watanabe M, Iizuka Y, Kubota T, Kitajima M, Kawakami Y. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Canc Gene Ther 2002, 9:142-148.
32. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148. 10.1016/j.immuni.2004.07.017, 15308095.
33. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360. 10.1146/annurev.immunol.22.012703.104803, 15032581.
34. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570. 10.1126/science.1203486, 21436444.
35. D'Acquisto F, Crompton T. CD3+CD4-CD8- (double negative) T cells: saviours or villains of the immune response?. Biochem Pharmacol 2011, 82:333-340. 10.1016/j.bcp.2011.05.019, 21640713.